Novo Nordisk advanced coramitug into the Phase III CLEOPATTRA trial, evaluating 1,280 patients with amyloid transthyretin cardiomyopathy or ATTR-CM. This decision was informed by results from their ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its fourth quarter and full year 2025 financial results and provided a corporate update.